# AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

- Link: https://www.directorstalkinterviews.com/astrazeneca-wins-us-approval-for-imfinzi-in-early-gastric-and-gej-cancers/4121227466
- Published: 2025-11-26T07:27:52+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))’
s _Imfinzi_ (durvalumab) in combination with standard-of-care FLOT chemotherapy (
fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US
for the treatment of adult patients with resectable, early-stage and locally advanced(
Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The approved
regimen includes neoadjuvant _Imfinzi_ in combination with chemotherapy before surgery,
followed by adjuvant _Imfinzi_ in combination with chemotherapy, then _Imfinzi_ 
monotherapy.

The approval follows Priority Review by the Food and Drug Administration (FDA) and
is based on event-free survival (EFS) and overall survival (OS) data from the MATTERHORN
Phase III trial_._ The EFS results were presented during the Plenary Session at 
the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously
published in The New England Journal of Medicine_._ OS results from MATTERHORN were
presented in a Proffered Paper session at the European Society for Medical Oncology(
ESMO) Congress 2025.

Gastric cancer is the fifth leading cause of cancer death globally, with nearly 
one million people diagnosed each year.^(1) In 2024, there were roughly 6,500 drug-
treated patients in the US in early-stage and locally advanced gastric or GEJ cancer.
^(2)

> **Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit,
> AstraZeneca, said**: “This approval ushers in a new clinical paradigm for patients
> with early gastric and gastroesophageal junction cancers, with _Imfinzi_ plus 
> FLOT delivering a durable survival benefit that increases over time. As the third
> US approval for a perioperative _Imfinzi_-based regimen, this milestone further
> validates the perioperative approach and underscores our focus on bringing novel
> treatments to early-stage cancers where cure is the goal.”

> **Yelena Y. Janjigian, MD, Chief Attending Physician of the Gastrointestinal Medical
> Oncology Service, Memorial Sloan Kettering Cancer Center (MSK), New York and principal
> investigator in the MATTERHORN trial, said**: “Today’s approval marks the first
> immunotherapy regimen approved in the neoadjuvant setting for gastric and gastroesophageal
> junction cancers-with durvalumab demonstrating a clear overall survival benefit
> and opening an entirely new chapter in the treatment of early-stage disease. Nearly
> seven in 10 patients were alive at three years following treatment with the durvalumab-
> based perioperative regimen. This survival benefit, observed regardless of PD-
> L1 status, establishes a new standard of care in this curative-intent setting.”

> **Aki Smith, Founder and Executive Director, Hope for Stomach Cancer, said**: “
> From personal experience as a caregiver to my father, I know that for too long
> patients diagnosed with early gastric or gastroesophageal junction cancer have
> faced a high risk of their cancer returning, even after undergoing surgery and
> therapy intended to cure it. Today’s approval represents a major step forward 
> in improving outcomes and offering renewed hope to those affected by this devastating
> disease.”

In a planned interim analysis, patients treated with the _Imfinzi_-based perioperative
regimen showed a 29% reduction in the risk of disease progression, recurrence or
death versus chemotherapy alone (based on an EFS hazard ratio [HR] of 0.71; 95% 
confidence interval [CI] 0.58-0.86; p<0.001). Estimated median EFS was not yet reached
for the _Imfinzi_ arm versus 32.8 months for the comparator arm. An estimated 78.2%
of patients treated with the _Imfinzi_-based perioperative regimen were event-free
at one year, compared to 74.0% in the comparator arm; the estimated 24-month EFS
rate was 67.4% versus 58.5%, respectively.

In the final OS analysis, results showed the _Imfinzi_ and FLOT perioperative regimen
reduced the risk of death by 22% compared with chemotherapy alone (based on a HR
of 0.78; 95% CI 0.63-0.96; p=0.021). An estimated 69% of patients treated with the
_Imfinzi_-based regimen were alive at three years compared with 62% in the FLOT-
only arm. With longer follow-up, the OS curves showed continued separation, signaling
a greater magnitude of benefit over time for the _Imfinzi_-based regimen. An OS 
benefit was observed regardless of PD-L1 status.

The safety profile for _Imfinzi_ and FLOT chemotherapy was consistent with the known
profiles of each medicine, and the percentage of patients that completed surgery
was similar compared to chemotherapy alone. Grade 3 or higher adverse events due
to any cause were similar between the two arms (71.6% for _Imfinzi_ and FLOT arm;
71.2% for FLOT-only arm).

The US regulatory submission was reviewed under Project Orbis, which provides a 
framework for concurrent submission and review of oncology medicines among participating
international partners. As part of Project Orbis, the _Imfinzi_ and FLOT perioperative
regimen is also under review by regulatory authorities in Australia, Canada, and
Switzerland for the same indication. Regulatory applications are also under review
in the European Union (EU), Japan and several other countries.

AstraZeneca has a broad development programme for the treatment of GI cancers across
several medicines and a variety of tumour types and stages of disease. In 2022, 
GI cancers collectively represented approximately 5 million new cancer cases leading
to approximately 3.3 million deaths.^(8)

_8.   World Health Organization. World Cancer Fact Sheet. Available at: https://
gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf.
Accessed November 2025._

Share on:
